2010 Major Sponsored Program and Faculty Awards - Office of ...
2010 Major Sponsored Program and Faculty Awards - Office of ...
2010 Major Sponsored Program and Faculty Awards - Office of ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Vel<strong>and</strong>er, William Chemical <strong>and</strong> Biomolecular EngineeringcGMP Recombinant FIX <strong>and</strong> Oral Hemophilia B Therapy$9,587,071 NIH-NHLBI9/6/05 – 8/31/11Van Cott, Kevin Chemical <strong>and</strong> Biomolecular EngineeringWilliam Vel<strong>and</strong>er, Donald R. Voelte Jr. <strong>and</strong>Nancy A. Keegan Endowed Chair inEngineering, is principal investigator in apartnership funded by a $9.9 million grantfrom the National Institutes <strong>of</strong> Health/National Heart, Lung <strong>and</strong> Blood Institute.The goal is to develop an abundant, pure,safe <strong>and</strong> effective therapy for Hemophilia B using recombinanthuman coagulation proteins produced in the milk <strong>of</strong> transgenicpigs. The project builds on innovative bioengineering technologiespioneered by Vel<strong>and</strong>er that enable improved intravenous <strong>and</strong> noveloral delivery <strong>of</strong> hemophilic factors to patients. Hemophilia B is acongenital bleeding disorder that causes pain, crippling injuries<strong>and</strong> early death. It can be treated by Factor IX, a blood protein, butthe costs are prohibitive <strong>and</strong> most patients do not receive it.Vel<strong>and</strong>er’s project isolates Factor IX in the milk <strong>of</strong> transgenic pigs.Production <strong>and</strong> Purification <strong>of</strong> Fibrinogen Componentsfor Production Fibrin Sealant <strong>of</strong> Hemostatic Dressing$5,398,990 DoD-AMR8/1/05 – 8/30/10Van Cott, Kevin Chemical <strong>and</strong> Biomolecular EngineeringWilliam Vel<strong>and</strong>er is also leading a project, funded by theDepartment <strong>of</strong> Defense, to develop processes to producerecombinant fibrinogen <strong>and</strong> other blood proteins for b<strong>and</strong>ages <strong>and</strong>implant devices, <strong>and</strong> to conduct research <strong>and</strong> clinical trials on theireffectiveness. The fibrinogen b<strong>and</strong>age is a potentially life-savingtechnology for patients who lose large amounts <strong>of</strong> blood. Whenapplied, the b<strong>and</strong>age immediately begins clotting the wound,stemming blood loss. The technology could be used in battlefieldor other applications where patients are hemorrhaging. Fibrinogentechnology could also play a role in helping develop implantabledevices with increased biological compatibility. Fibrinogen madefrom human plasma is scarce <strong>and</strong> expensive; Vel<strong>and</strong>er hasdeveloped a process for producing it from transgenic cattle bredwith a human gene that enables them to produce fibrinogen.Whitbeck, LesSociologyOjibwe Pathways Through the High School Years$3,121,678 NIH-NIDA9/3/05 – 6/30/12Johnson, KurtSociologyLes Whitbeck, John G. Bruhn Pr<strong>of</strong>essor <strong>of</strong>Sociology, is coordinating a seven-yearproject, funded by the National Institute onDrug Abuse, to investigate risk <strong>and</strong> resiliencefor early onset substance use <strong>and</strong> abuseamong pre-teen Native children in the UpperMidwest.20AWARDS OF $3 MILLION OR MORE
Change language